Summary
Seventeen hospitalized patients (age 39–66 years), received a loading dose of 100 mg imipramine HCl and then 50 mg b.i.d. The 12-h plasma concentration at steady-state varied between 40–637 nmol/l for imipramine, 49–1148 nmol/l for desipramine and 89–1603 nmol/l for imipramine + desipramine. Guided by plasma level monitoring, a final therapeutic plasma level between 548–910 nmol/l for imipramine + desipramine was achieved (therapeutic dose range: 50–400 mg/day). Mean time to reach the therapeutic level was 19 days. The mean 2-OH-imipramine/imipramine ratio was 0.24 and mean 2-OH-desipramine/desipramine ratio was 0.56. There was a significant intrapatient correlation between the two ratios, both during 100 mg imipramine/d and at the therapeutic dose level. A low ratio was associated with high imipramine and particularly with a high desipramine level. Well defined steady state levels were established at two different dose levels in 12 patients and at three dose levels in 5 patients. With increasing dose there was a marked and disproportionate rise in the desipramine level and to some extent in the imipramine level. Saturation of imipramine and desipramine hydroxylation appeared to be responsible for the dose-dependent kinetics. Concomitant treatment with levomepromazine and perphenazine in one patient resulted in a significant rise both in imipramine and desipramine concentration, apparently due to inhibition of the hydroxylation. Eleven out of twelve endogenously depressed patients responded completely to treatment, whereas the response was poor in the non-endogenously depressed patients despite optimal drug levels.
Similar content being viewed by others
References
Alexanderson B (1972) Pharmacokinetics of desmethylimipramine and nortriptyline in man after single and multiple oral doses. Eur J Clin Pharmacol 5: 1–10
Bjerre M, Gram LF, Kragh-Sørensen P, Kristensen CB, Pedersen OL, Møller M, Thayssen P (1981) Dose-dependent kinetics of imipramine in elderly patients. Psychopharmacology 75: 354–357
Christiansen J, Gram LF, Kofod B, Rafaelsen OJ (1967) Imipramine metabolism in man. Psychopharmacologia 11: 255–264
Cooke RG, Warsh JJ, Stancer HC, Reed KL, Persad E (1984) The non-linear kinetics of desipramine and 2-hydroxydesipramine in plasma. Clin Pharmacol Ther 36: 343–349
Crammer JL, Scott B, Rolfe B (1969) Metabolism of14C-imipramine: II. Urinary metabolites in man. Psychopharmacologia 15: 207–225
De Vane CL, Jusko WJ (1981) Plasma concentration monitoring of hydroxylated metabolites of imipramine and desipramine. Drug Intell Clin Pharm 15: 263–266
Dencker H, Dencker SJ, Green A, Nagy A (1976) Intestinal absorption, demethylation and enterohepatic circulation of imipramine. Clin Pharmacol Ther 19: 584–586
Eichelbaum M (1982) Defective oxidation of drugs: Pharmacokinetic and therapeutic implications. Clin Pharmacokinet 7: 1–22
Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL (1977) Clinical implication of imipramine plasma levels for depressive illness. Arch Gen Psychiatr 34: 197–204
Goth A (1984) Medical pharmacology, 11 edn. C. V. Mosby & Co., St. Louis, pp 269–277
Gram LF, Overø KF (1972) Drug interaction: Inhibitory effects of neuroleptics on metabolism of tricyclic antidepressants in man. Br. Med J 163: 463–465
Gram LF (1975) Effects of perphenazine on imipramine metabolism in man. Psychopharmacol Commun 1: 165–175
Gram LF, Christiansen J (1975) First-pass metabolism of imipramine in man. Clin Pharmacol Ther 17: 555–563
Gram LF, Søndergaard I, Christiansen J, Petersen GO, Bech P, Reisby N, Ibsen I, Ortmann J, Nagy A, Dencker SJ, Jacobsen O, Krautwald O (1977) Steady state kinetics of imipramine in patients. Psychopharmacology 54: 255–261
Gram LF (1978) Plasma level monitoring of tricyclic antidepressants: Methodological and pharmacokinetic considerations. Commun Psychopharmacol 2: 373–380
Gram LF, Bjerre M, Kragh-Sørensen P, Kvinesdal B, Molin J, Pedersen OL, Reisby N (1983) Imipramine metabolites in blood during therapy and after overdose. Clin Pharmacol Ther 33: 335–342
Gram LF, Kragh-Sørensen P, Kristensen CB, Møller M, Pedersen OL, Thayssen P (1984) Plasma level monitoring of antidepressants: Theoretical basis and clinical application. In: Usdin E, Asberg M, Bertilsson L, Sjöqvist F (eds) Frontiers in biochemical and pharmacological research in depression. Raven Press, New York, pp 399–411
Jandhyala BS, Steenberg ML, Perel JM, Manian AA, Buckley JP (1977) Effects of several tricyclic antidepressants on the hemodynamics and myocardial contractility of the anesthetized dog. Eur J Pharmacol 42: 403–410
Javaid JI, Perel JM, Davis J-M: Inhibition of biogenic amines uptake by imipramine, desipramine, 2-OH-imipramine and 2-OH-desipramine in rat brain. Life Sci 24: 21–28
Kragh-Sørensen P, Hansen CE, Åsberg M: Plasma levels of nortriptyline in the treatment of endogenous depression. Acta Psychiatr Scand 49: 444–456
Olivier-Martin R, Marzin D, Buschenschutz E, Pichot P, Baissier J (1975) Concentrations plasmatique de l'imipramine et de la desmethylimipramine et effet anti-depresseur au cours d'un traitement controlé. Psychopharmacologia 41: 187–195
Potter WZ, Calil HM, Manian AA, Zavadil AP, Goodwin FK (1979) Hydroxylated metabolites of tricyclic antidepressants: Preclinical assessment of activity. Biol Psychiatr 14: 601–613
Potter WZ, Calil HM, Sutfin TA, Zavadil AP, Jusko WJ, Rapaport J, Goodwin FK (1982) Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther 31: 393–401
Reisby N, Gram LF, Bech P, Nagy A, Petersen GO, Ortmann J, Ibsen I, Dencker SJ, Jacobsen OJ, Krautwald O. Søndergaard I, Christiansen J (1977) Imipramine: Clinical effects and pharmacokinetic variability. Psychopharmacology 54: 263–272
Rowland M, Tozer TN (1980) Clinical pharmacokinetics: Concepts and applications. Lea & Feiger, Philadelphia, pp 124–137
Spina E, Birgersson C, von Bahr C, Ericsson O, Mellström B, Steiner E, Sjöqvist F (1984) Phenotypic consistency in the hydroxylation of demethylimipramine and debrisoquine in healthy volunteers and in human liver microsomes. Clin Pharmacol Ther 36: 677–682
Sutfin TA, De Vane CL, Jusko WJ (1984) The analysis and disposition of imipramine and its active metabolites in man. Psychopharmacology 82: 310–317
Tsuchiya T, Levy U (1972) Relationship between dose and plateau levels of drugs eliminated by parallel first oder and capacitylimited kinetics. J Pharm Sci 61: 541–544
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brøsen, K., Gram, L.F., Klysner, R. et al. Steady-state levels of imipramine and its metabolites: Significance of dose-dependent kinetics. Eur J Clin Pharmacol 30, 43–49 (1986). https://doi.org/10.1007/BF00614194
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00614194